Generation of a Novel Mesothelin-Targeted Oncolytic Herpes Virus and Implemented Strategies for Manufacturing
Authors:
- Guendalina FroechlichGFGuendalina Froechlich
- Chiara GentileCGChiara Gentile
- Luigia InfanteLILuigia Infante
- Carmen CaiazzaCCCarmen Caiazza
- Pasqualina PaganoPPPasqualina Pagano
- Sarah ScatignaSSSarah Scatigna
- Gabriella CotugnoGCGabriella Cotugno
- Anna Morena D’aliseADAnna Morena D’alise
- Armin LahmALArmin Lahm
- Elisa ScarselliESElisa Scarselli
- Alfredo NicosiaANAlfredo Nicosia
- Massimo MallardoMassimo Mallardo
Open Access
- 6 January 2021
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (2) , 477
Abstract
Background: HER2-based retargeted viruses are in advanced phases of preclinical development of breast cancer models. Mesothelin (MSLN) is a cell-surface tumor antigen expressed in different subtypes of breast and non-breast cancer. Its recent identification as a marker of some triple-negative breast tumors renders it an attractive target, presently investigated in clinical trials employing antibody drug conjugates and CAR-T cells. The availability of MSLN-retargeted oncolytic viruses may complement the current immunotherapeutic panel of biological drugs against HER2-negative breast and non-breast tumors. Methods: A fully virulent, tumor-targeted oncolytic Herpes simplex virus-1 (MSLN-THV) with a selectivity for mesothelin-expressing cancer cells was generated. Recombineering technology was used to replace an essential moiety of the viral glycoprotein D with antibody fragments derived from clinically validated MSLN monoclonal antibodies, and to allow IL12 cargo expression in infected cells. Panels of breast and female reproductive system cell lines were used to verify the oncolytic potential of the viral constructs. A platform for production of the retargeted viruses was developed in HEK 293 cells, providing stable expression of a suitable chimeric receptor. Results: We demonstrated the selectivity of viral infection and cytotoxicity by MSLN-retargeted viruses in a panel of mesothelin-positive cancer cells, originating from breast and female reproductive system tumors. We also developed a second-generation oncolytic MSLN-THV, encoding IL12, to enhance the immunotherapeutic potential of the viral backbone. A non-tumor cell line expressing a chimeric MSLN/Nectin-1 receptor, de-sensitized from antiviral responses by genetic inactivation of the Stimulator of Interferon Genes (STING)-dependent pathway was engineered, to optimize viral yields. Conclusions: Our proof-of-concept study proposes MSLN-retargeted herpesviruses as potential cancer immunotherapeutics for assessments in preclinical models of MSLN-positive tumors, complementing the available panel of oncolytic viruses to HER2-negative breast tumors.Keywords
Funding Information
- Regione Campania (SATIN)
- Consorzio Interuniversitario Biotecnologie (CIB)
- Discimus (Terapia dei tumori ipossici)
This publication has 95 references indexed in Scilit:
- Mesothelin-Targeted Agents in Clinical Trials and in Preclinical DevelopmentMolecular Cancer Therapeutics, 2012
- Redirected Antitumor Activity of Primary Human Lymphocytes Transduced With a Fully Human Anti-mesothelin Chimeric ReceptorMolecular Therapy, 2012
- Herpes simplex virus infects most cell types in vitro: clues to its successVirology Journal, 2011
- STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunityNature, 2009
- Construction of a Fully Retargeted Herpes Simplex Virus 1 Recombinant Capable of Entering Cells Solely via Human Epidermal Growth Factor Receptor 2Journal of Virology, 2008
- STING is an endoplasmic reticulum adaptor that facilitates innate immune signallingNature, 2008
- Aberrant splicing and protease involvement in mesothelin release from epithelioid mesothelioma cellsCancer Science, 2008
- Genevestigator V3: A Reference Expression Database for the Meta‐Analysis of TranscriptomesAdvances in Bioinformatics, 2008
- Mesothelin Variant 1 Is Released from Tumor Cells as a Diagnostic MarkerCancer Epidemiology, Biomarkers & Prevention, 2006
- Characterization of a Recombinant Herpes Simplex Virus 1 Designed To Enter Cells via the IL13Rα2 Receptor of Malignant Glioma CellsJournal of Virology, 2005